MIRA Pharmaceuticals, Inc.
MIRA
$1.07
$0.172819.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 55.43% | -9.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.11% | 20.28% | |||
| Operating Income | -17.11% | -20.28% | |||
| Income Before Tax | -17.41% | -20.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.41% | -20.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.41% | -20.85% | |||
| EBIT | -17.11% | -20.28% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -6.86% | -18.53% | |||
| Normalized Basic EPS | -6.84% | -18.60% | |||
| EPS Diluted | -6.86% | -18.53% | |||
| Normalized Diluted EPS | -6.84% | -18.60% | |||
| Average Basic Shares Outstanding | 9.88% | 1.97% | |||
| Average Diluted Shares Outstanding | 9.88% | 1.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||